Gathering the record
Relay is organizing the evidence and source boundaries.
Informal two-component combination label
Wolverine is a community name for using BPC-157 and TB-500 together. No controlled or registered study of the verified combination was located. FDA summarized one confounded adverse-event report naming both materials, while a tiny knee report used BPC-157 plus unverified thymosin beta-4 material.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Wolverine is a community name for using BPC-157 and TB-500 together. It is not one standardized compound, and the available records do not establish a reproducible fixed-combination product.
The name combines two repair-related hypotheses. Direct combination evidence matters because shared marketing themes do not answer whether the materials are compatible, interact, or produce the same effects together.
No controlled or registered study of a chemically verified BPC-157 and TB-500 combination was located. The human record consists of a confounded adverse-event report and a four-person subgroup that received BPC-157 plus material described as thymosin beta-4, without verifying that material as TB-500.
Identity, ratio, stability, sterility, pharmacokinetics, interactions, immunogenicity, adverse-event frequency, safety, and clinical outcomes of the actual mixture remain unknown. Separate component records cannot establish a combination effect.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
No controlled study was located that administered chemically verified BPC-157 and TB-500 together as a standardized combination.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
The human combination record is limited to one confounded adverse-event report and a four-person subgroup using unverified thymosin-beta-4 material.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
No controlled trial verifies TB-500 exposure, isolates a combination effect, measures pharmacokinetics, or establishes adverse-event incidence.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: A voluntary adverse-event report cannot establish incidence or causation, and a four-person uncontrolled subgroup did not verify the second material as TB-500. The section remains incomplete because combination identity, compatibility, exposure, safety, and outcome evidence are absent. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
For the combination, one confounded FDA adverse-event report and a four-person subgroup exposed to BPC-157 plus material described as thymosin beta-4. Neither establishes benefit, safety, or verified TB-500 exposure in a controlled study.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Verified product identity, ratio, compatibility, stability, pharmacokinetics, interactions, immunogenicity, dose-response, adverse-event incidence, safety, and clinical effects of the actual two-component mixture.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Peptide Relay uses the name to organize discussion of mixtures described as BPC-157 and TB-500. The label does not define a regulator-recognized identity, fixed ratio, salt form, formulation, or quality standard.
Searches of PubMed and ClinicalTrials.gov through July 25, 2026 did not identify a controlled or registered trial administering the verified two-component combination.
A 40-year-old woman reportedly developed diffuse skin hyperpigmentation and gingival darkening while using both materials, with recurrence upon rechallenge.
Only four people received BPC-157 plus material described as thymosin beta-4, there was no randomized comparison, and the report did not verify that the second material was TB-500.
BPC-157 has no identified molecular target, while TB-500 is discussed through fragment and actin-region hypotheses. Different proposed pathways do not show that the materials improve one another's effects.
No located study tested whether BPC-157 and TB-500 remain chemically and physically stable together, avoid aggregation, retain identity and potency, or produce a favorable biological interaction.
No approved fixed-combination product or clinical trial provides a universal preparation, administration, or handling process for BPC-157 plus TB-500.
PCAC recommended possible 503A-list inclusion of BPC-157 and TB-500-related substances, but those votes were nonbinding and did not evaluate or approve a fixed-combination product.
BPC-157 appears under S0 non-approved substances, while thymosin beta-4 and derivatives such as TB-500 are listed under S2.
Mechanisms
The Wolverine label combines two distinct investigational peptides with uneven evidence records. BPC-157 has predominantly preclinical evidence, several small uncontrolled human reports, an incompletely reported historical controlled study, and a recruiting Phase 2 trial without results. TB-500 is a seven-amino-acid thymosin beta-4 fragment with laboratory and animal evidence but no located controlled human study. No pharmacokinetic, compatibility, stability, interaction, safety, or efficacy trial of verified BPC-157 plus TB-500 was located. FDA's BPC-157 review summarized one voluntary adverse-event report naming both materials; that signal cannot establish causation or incidence.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Open-label, two-person intravenous BPC-157 safety observation
Two healthy adults
The two participants had no reported adverse effects or meaningful short-term laboratory changes during the pilot.
Study administration: Intravenous BPC-157 under the pilot protocol; no TB-500
Limitations: Two short BPC-157-only observations cannot establish a population safety profile and provide no information about TB-500 or the combination.
TB-500 metabolism in human-derived in-vitro systems and rats, with fibroblast scratch-wound assays
Human serum and microsomal systems, cultured fibroblasts, and rats
Parent TB-500 did not improve fibroblast scratch-wound closure at the tested concentration; one shorter metabolite showed activity.
Study administration: TB-500 free base and synthesized metabolites under laboratory protocols; no BPC-157
Limitations: Laboratory and animal findings do not establish human TB-500 benefit, BPC-157 interaction, mixture compatibility, or a Wolverine-combination effect.
Uncontrolled retrospective chart review with follow-up questions
Sixteen people treated for heterogeneous chronic knee-pain conditions; four received two materials
Fourteen of 16 people reported some relief overall. Three of the four people in the two-material subgroup reported relief, but the study did not compare that subgroup with a randomized control.
Study administration: Twelve people received BPC-157 alone; the first four also received material described as thymosin beta-4. The report did not verify that material as the seven-amino-acid TB-500 fragment.
Limitations: The report was retrospective, uncontrolled, unblinded, and based on subjective outcomes. Only four people received two materials, and the second material was not chemically verified as TB-500. It cannot establish a Wolverine-combination effect.
Randomized, double-blind, placebo-controlled BPC-157 trial with standardized rehabilitation
Adults aged 18–45 with MRI-confirmed acute grade II hamstring strain
No results are posted. The registration cannot establish benefit for BPC-157 or for the Wolverine combination.
Study administration: Protocol-defined subcutaneous investigational BPC-157 or placebo; no TB-500
Limitations: This recruiting BPC-157-only trial has no posted results and does not test TB-500, the Wolverine combination, compatibility, or combined safety.
Voluntary FAERS report summarized in FDA's July 2026 BPC-157 evidence review
One 40-year-old woman
FDA summarized diffuse hyperpigmentation and gingival darkening that reportedly recurred when the combination was restarted.
Study administration: Self-reported subcutaneous BPC-157 and TB500 twice daily; product identity, dose exposure, and concomitant substances were not independently verified
Limitations: A voluntary report cannot establish incidence or causation. FDA noted missing information and possible confounding, including concomitant medications. Product identity, purity, sterility, dose exposure, and attribution to either component or the combination were not established.
Safety snapshot
FDA summarized one adverse-event report naming concurrent BPC-157 and TB500 exposure.
Other human evidenceThe report does not establish causation, incidence, product identity, or which material was responsible. FDA emphasized missing information and confounding factors.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNo FDA-approved BPC-157/TB-500 fixed-combination product was located. PCAC recommendations concerning each ingredient are nonbinding and do not approve the combination. Both components are prohibited in sport. Verified product identity, ratio, compatibility, stability, pharmacokinetics, interactions, immunogenicity, dose-response, adverse-event incidence, safety, and clinical effects of the actual two-component mixture.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-07-25
2026-07-25
2026-07-23
2026-07-21
2026-02-27 · NCT07437547
2026-01-01
2025-09-01 · PMID 40131143
2024-03-15 · PMID 38382158 · DOI 10.1016/j.jchromb.2024.124033
2021-07-01 · PMID 34324435
No direct primary administration source was verified for this exact identity. The limitation is the finding.